title: Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR.
authors.forename: Myung-Ju
authors.initials: MJ
authors.lastname: Ahn
authors.forename: Sang-We
authors.initials: SW
authors.lastname: Kim
authors.forename: Byoung-Chul
authors.initials: BC
authors.lastname: Cho
authors.forename: Jin Seok
authors.initials: JS
authors.lastname: Ahn
authors.forename: Dae Ho
authors.initials: DH
authors.lastname: Lee
authors.forename: Jong-Mu
authors.initials: JM
authors.lastname: Sun
authors.forename: Dan
authors.initials: D
authors.lastname: Massey
authors.forename: Miyoung
authors.initials: M
authors.lastname: Kim
authors.forename: Yang
authors.initials: Y
authors.lastname: Shi
authors.forename: Keunchil
authors.initials: K
authors.lastname: Park